Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression

Growing evidence suggests that the glutamatergic modulator ketamine has rapid antidepressant effects in treatment-resistant depressed subjects. The anticholinergic agent scopolamine has also shown promise as a rapid-acting antidepressant. This study applied genome-wide markers to investigate the rol...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Translational psychiatry 2018-12, Vol.8 (1), p.280-8, Article 280
Hauptverfasser:	Guo, Wei, Machado-Vieira, Rodrigo, Mathew, Sanjay, Murrough, James W., Charney, Dennis S., Grunebaum, Matthew, Oquendo, Maria A., Kadriu, Bashkim, Akula, Nirmala, Henter, Ioline, Yuan, Peixiong, Merikangas, Kathleen, Drevets, Wayne, Furey, Maura, Mann, J. John, McMahon, Francis J., Zarate Jr, Carlos A., Shugart, Yin Yao
Format:	Artikel
Sprache:	eng
Schlagworte:	45 45/43 692/53/2423 692/699/476/1414 Adolescent Adult Aged Antidepressants Antidepressive Agents - therapeutic use Behavioral Sciences Biological Psychology Bipolar Disorder - drug therapy Bipolar Disorder - genetics Depressive Disorder, Major - drug therapy Depressive Disorder, Major - genetics Female Genetic Predisposition to Disease Genome-Wide Association Study Genomes Humans Ketamine Ketamine - therapeutic use Male Medicine Medicine & Public Health Mental depression Middle Aged Multifactorial Inheritance Neurosciences Pharmacogenomic Testing Pharmacotherapy Pilot Projects Polymorphism, Single Nucleotide Psychiatric Status Rating Scales Psychiatry Risk Factors Scopolamine - therapeutic use Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!